idw – Informationsdienst Wissenschaft

Nachrichten, Termine, Experten

Grafik: idw-Logo
Science Video Project

idw-News App:


Google Play Store

24.05.2024 10:58

Early Intensified Treatment Cuts Type 2 Diabetes Burden by USD 23 Million in Korea

Katja Wies Kommunikation

    A recent study by WifOR Institute highlights the societal benefits of early intensified treatment for Type 2 diabetes patients in Korea. Over a ten-year period,12% more patients who started combination therapy during the early stages of the disease achieved sustained glycemic control compared to those who began with monotherapy. Additionally, early intensified antidiabetes treatment resulted in a 14% reduction in diabetes-related complication events over the same period. These therapy strategies prevented 1.56 million lost work hours (649,696 paid, 919,444 unpaid) over a decade for the entire population, resulting in USD 23 million economic gain for Korea.

    Dr. Malina Müller, Head of Health Economics at WifOR Institute: “Our Social Impact analysis reveals with hard numbers that early intensified antidiabetes treatment not only improves patients' health but also elevates their productivity and social engagement, benefiting both patients and their caregivers. These findings enable decision-makers to weigh the medical efficacy alongside health interventions' broader societal and economic effects.”

    The study, “Health and Productivity Benefits with Early Intensified Treatment in Patients with Type 2 Diabetes: Results from Korea”, was commissioned by Novartis and published in the May 2024 edition of the renowned journal “INQUIRY: The Journal of Health Care Organization, Provision, and Financing.”

    Study Background:
    The prevalence of diabetes mellitus (DM) worldwide is a pressing concern, with Type 2 diabetes mellitus (T2DM) accounting for approximately 90% of cases. In Korea, the economic burden of diabetes has prompted research into early and customized treatment strategies. These strategies enable effective disease control and reduce the risk of complications. However, budget constraints within healthcare systems challenge the implementation of these approaches. WifOR Institute's Social Impact analysis underscores the importance of early intervention and tailored treatments in managing T2DM, not only for individual patient outcomes but also for wider societal and economic well-being.

    About the Social Impact approach:
    The Social Impact of medical innovations quantifies and monetizes the productivity losses of paid and unpaid work which can be avoided due to a health intervention. Early intensified antidiabetes treatment improves chronically ill patients' ability to work and pursue daily activities. In addition, the potential for value creation resulting from unpaid work is considered. WifOR thus holistically measures the benefit to society regarding health and productivity effects.

    Utilizing a robust simulation model based on data from the VERIFY clinical trial and real-world evidence, the study compares outcomes of two treatment regimens: early intensified treatment (combination therapy with metformin and vildagliptin) versus a conventional stepwise approach (initial metformin monotherapy followed by combination therapy). It covers a 10-year horizon with 6-month cycles and assesses probabilities of complications like stroke, myocardial infarction, and neuropathy. Population size is estimated based on Korean T2DM prevalence and the percentage of patients receiving any antidiabetes treatment subsequently controlled for the patients expected to receive early intensified treatment. Productivity losses are evaluated using Korean employment data. Both deterministic and probabilistic sensitivity analyses are conducted to assess parameter uncertainty.

    About WifOR Institute

    WifOR is an independent economic research institute, founded in 2009 as a spin-off from the Technical University of Darmstadt. As experts in macroeconomic analysis, our research focuses on labor markets, health, and sustainability. Through our studies, WifOR’s mission is to enable data-based solutions to labor market challenges, set global standards in sustainability measurement, and illuminate the value of health investments worldwide. WifOR has over 75 employees in Germany, Greece, Latin America, and the USA.

    Wissenschaftliche Ansprechpartner:

    Foteini Tsotra
    Researcher Health Economics


    Tsotra, F., Malhotra, A., Peristeris, P., Athanasiou, I., Müller, M., & Bader, G. (2024). Health and Productivity Benefits with Early Intensified Treatment in Patients with Type 2 Diabetes: Results from Korea. INQUIRY: The Journal of Health Care Organization, Provision, and Financing. Vol. 61,1-8. DOI:

    Weitere Informationen:


    WifOR Study Finds Early Intensified Treatments Cut Type 2 Diabetes Burden by USD 23 Million in Korea
    WifOR Study Finds Early Intensified Treatments Cut Type 2 Diabetes Burden by USD 23 Million in Korea

    WifOR Institute

    Merkmale dieser Pressemitteilung:
    Journalisten, Lehrer/Schüler, Studierende, Wirtschaftsvertreter, Wissenschaftler, jedermann
    Medizin, Wirtschaft
    Forschungsergebnisse, Wissenschaftliche Publikationen


    WifOR Study Finds Early Intensified Treatments Cut Type 2 Diabetes Burden by USD 23 Million in Korea

    Zum Download



    Die Suche / Erweiterte Suche im idw-Archiv

    Sie können Suchbegriffe mit und, oder und / oder nicht verknüpfen, z. B. Philo nicht logie.


    Verknüpfungen können Sie mit Klammern voneinander trennen, z. B. (Philo nicht logie) oder (Psycho und logie).


    Zusammenhängende Worte werden als Wortgruppe gesucht, wenn Sie sie in Anführungsstriche setzen, z. B. „Bundesrepublik Deutschland“.


    Die Erweiterte Suche können Sie auch nutzen, ohne Suchbegriffe einzugeben. Sie orientiert sich dann an den Kriterien, die Sie ausgewählt haben (z. B. nach dem Land oder dem Sachgebiet).

    Haben Sie in einer Kategorie kein Kriterium ausgewählt, wird die gesamte Kategorie durchsucht (z.B. alle Sachgebiete oder alle Länder).